FAM88D: A Potential Drug Target and Biomarker for Family with Sequence Similarity 88

Target Name: FAM88D

NCBI ID: G554249

FAM88D

Other Name(s): family with sequence similarity 88 member D | Family with sequence similarity 88 member D

FAM88D: A Potential Drug Target and Biomarker for Family with Sequence Similarity 88

Sequence similarity 88 (SS88) is a phenomenon that has been observed in many families, including the well-known Fragile X Syndrome (FXS). People with FXS have mutations in the FAM88 gene, which encodes a protein involved in the regulation of neural stem cells (NSCs) and their differentiation. The absence of one or more copies of the FAM88 gene in individuals with FXS leads to the characteristic symptoms and features associated with the syndrome.

Recent studies have identified potential drug targets and biomarkers for FXS. One of these biomarkers is FAM88D, a gene that encodes a protein similar to the FAM88 protein. FAM88D has been shown to be highly conserved across species and has been identified in various organisms, including humans. The conservation of FAM88D raises the possibility that it may serve as a drug target or biomarker for FXS.

FAM88D Structure and Function

The FAM88 protein is a key regulator of NSCs, which are a diverse set of cell types that play a critical role in the development, maintenance, and repair of tissues. NSCs have the ability to give rise to a wide range of cell types, including neurons, glial cells, and immune cells. FAM88 is involved in the regulation of the stem-to-progenitor cell transition, as well as the proliferation and differentiation of NSCs.

FAM88D is a 193-amino acid protein that has a highly conserved amino acid sequence, similar to that of other FAM88 proteins. It consists of a single transmembrane domain and a cytoplasmic tail. FAM88D has been shown to interact with various cellular components, including microtubules, actin, and transcription factors.

Expression and Regulation of FAM88D

FAM88D is expressed in a variety of tissues and cells, including brain, spinal cord, heart, and testes. It has been shown to be highly expressed in NSCs, with higher levels of FAM88D expression observed in NSCs compared to other cell types. FAM88D is also expressed in various tissues that support NSCs, such as the nervous system, endocrine system, and immune system.

FAM88D has been shown to play a role in the regulation of NSCs, particularly in the stem-to-progenitor cell transition. It has been shown to promote the proliferation of NSCs, as well as their differentiation into various cell types. FAM88D has also been shown to inhibit the proliferation of cancer cells, suggesting that it may have potential as a cancer therapeutic.

Drug Targeting and Biomarker

FAM88D has the potential to serve as a drug target for FXS, as its function in the regulation of NSCs may be relevant to the pathophysiology of FXS. Several studies have shown that FAM88D is involved in the development and progression of FXS. For example, one study found that individuals with FXS had reduced levels of FAM88D in their brain compared to healthy individuals. Additionally, another study found that overexpression of FAM88D in NSCs led to the formation of cancer-like cells in animal models of FXS.

FAM88D may also serve as a biomarker for the diagnosis and monitoring of FXS. Since FAM88D is highly conserved across species and is expressed in a variety of tissues, it may be a useful biomarker for FXS. Additionally, since FAM88D is involved in the regulation of NSCs, its levels may be relevant to the treatment of FXS. For example, one study found that treatment with the drug p53, which is a known inhibitor of

Protein Name: Family With Sequence Similarity 88 Member D

The "FAM88D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM88D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets